Sai Parenterals Board Approves Q1 FY27 Results, Key Reappointments & IPO Fund Diversion
Sai Parenterals Limited reported Q1 FY27 results with standalone revenue at ₹52.78 crore and consolidated revenue at ₹178.67 crore. The board approved re-appointments of Anil Kumar Karusala as MD and Vijitha Gorrepati as Whole-time Director. IPO proceeds of ₹83.83 crore will be diverted to acquire Saicriti Pharma and ₹18.02 crore to acquire Prathyak Laboratories. The AGM is scheduled for September 10, 2026.
The decision to divert IPO proceeds for acquisitions of Saicriti Pharma and Prathyak Laboratories, along with key management re-appointments and approval of financial results, has a significant impact on the company's strategic direction and future growth prospects.
The company reported financial results and approved several key strategic decisions, including re-appointments of key management personnel, acquisition of companies using IPO proceeds, and the incorporation of a foreign subsidiary, indicating proactive business development.
Sai Parenterals Limited announced the outcome of its Board Meeting held on August 11, 2026. The board approved the un-audited financial results, both standalone and consolidated, for the quarter ended June 30, 2026, along with the limited review report.
Key personnel changes were also approved. Mr. Anil Kumar Karusala was re-appointed as Director retiring by rotation and as Managing Director for three years effective January 1, 2027. Mrs. Vijitha Gorrepati was re-appointed as Whole-time Director for three years effective January 1, 2027. Mr. Kunal Kakumanu was appointed as Additional and Executive Director for three years effective August 11, 2026.
The board also approved the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer on or before October 12, 2026, and the resignation of Mrs. Aruna Karusala as Non-Executive Director effective August 11, 2026.
Significant variations in the utilization of IPO proceeds were approved. Approximately ₹838.34 million (83.83 crore) originally earmarked for manufacturing facility upgrades will now be used for acquiring 60% equity in Saicriti Pharma Private Limited. Additionally, ₹180.23 million (18.02 crore) for establishing an R&D center will be used to acquire 60% equity in Prathyak Laboratories Private Limited. Both acquisitions are subject to shareholder approval and are expected to be completed before October 30, 2026.
The board also approved the ratification of the Sai Parenterals Limited Employee Stock Option Plan, 2025 (ESOP Scheme-2025) and its extension to subsidiary companies, subject to shareholder approval. The incorporation of a new wholly-owned subsidiary in the United States of America was also approved.
Further, material related party transactions were approved, including a loan to Sai Singapore Pte. Ltd. for downstream funding to Noumed Pharmaceuticals Pty. Limited, and sale of goods/services with Noumed Pharmaceuticals Pty. Limited for FY 2026-27, both subject to shareholder approval.
The notice of the Annual General Meeting (AGM), Directors' Report, MD&A, and Corporate Governance Report for FY ended March 31, 2026, were approved. The AGM is scheduled for September 10, 2026.
Reconstitution of the Board Committees, including the Nomination and Remuneration Committee and Stakeholders Relationship Committee, was effective from August 11, 2026. The composition of the POSH Committee was also reconstituted.
The standalone revenue from operations for the quarter ended June 30, 2026, was ₹52.78 crore (527.79 million), with a profit after tax of ₹8.87 crore (88.75 million). The consolidated revenue from operations was ₹178.67 crore (1824.13 million), with a profit after tax of ₹7.92 crore (79.23 million).
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.